The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Solid Lipid Nanoparticles for Sustained Release of siRNAs


Stanford Reference:

11-144


Abstract


Researchers in Dr. Richard Zare’s lab have developed solid lipid nanoparticles (SLNPs) that provide sustained in vivo delivery of small interfering RNAs (siRNAs). siRNAs can silence genes responsible for disease, which makes them promising tools for gene therapy. However, in vivo delivery of siRNAs remains challenging due to lack of safe, efficient, and sustained delivery systems. siRNAs are rapidly degraded in the plasma and cellular cytoplasm resulting in short siRNA activity. To overcome these limitations the inventors have created new SLNPs to encapsulate and protect the siRNA and provide sustained in vivo siRNA delivery.


Illustration shows the in vivo release data of fluorescently labeled siRNA. Left- release data of free (unencapsulated) siRNA. Right- release of siRNA from SLNPs. SLNPs are coated with lipids (orange) and other molecules and contain siRNA (red) in complex with a positively charged lipid (purple).

Stage of Research
The inventors have shown that the SLNPs provide sustained release of siRNA in vivo and in vitro over a period of 10-13 days with retained functionality.


Applications


  • RNAi-based therapeutics

Advantages


  • Allows sustained release of siRNA
  • Biocompatible
  • Minimal toxicity
  • Less costly than polymeric carriers

Publications



Related Web Links



Innovators & Portfolio



Date Released

 7/2/2013
 

Licensing Contact


Evan Elder, Licensing Associate
650-725-9558 (Mobile)
Login to Request Information

[-] Map/Timeline

97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
99-158 Plasmid DNA vectors that integrate into host chromosomal DNA in vivo [Sleeping Beauty]
00-003 Altered recombinases for genome modification ("Shuffled" recombinases)

more technologies

Related Keywords


gene therapy   Solid Lipid Nanoparticles   sustained siRNA delivery   gene silencing   nanoparticles   therapeutic: RNAi   miRNA   siRNA   microRNA therapeutics   microRNA   materials: nanoparticle   nanoparticles drug delivery   therapeutic: gene therapy   shRNA   RNAi   RNA therapeutic   
 

   

  

Also of Interest...
97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
99-158 Plasmid DNA vectors that integrate into host chromosomal DNA in vivo [Sleeping Beauty]
00-003 Altered recombinases for genome modification ("Shuffled" recombinases)

Recently Viewed...
S11-144 Solid Lipid Nanoparticles for Sustained Release of siRNAs